Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial
- Conditions
- Early Stage Non-small Cell Lung Cancer
- Registration Number
- NCT01138722
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.
The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
- Proof of cT1a/b - 2a/b N0M0 NSCLC
- Informed Consent signed
- Resectable tumour
- Operable patient
- > 18 years old
- men and women
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method pathological effects of hypofractionated radiation therapy at 2 years To describe the pathological effects of hypofractionated radioation therapy (RT) and to address the relationship with blood and tissue biomarkers and bio-imaging.
- Secondary Outcome Measures
Name Time Method clinical response rate from 2 to 5 years progression free survival from 2 to 5 years overall survival from 2 to 5 years the accuracy of clinical mediastinal staging from 2 to 5 years the complication rate from 2 to 5 years local, regional or distant failure from 2 to 5 years disease specific overall survival from 2 to 5 years
Trial Locations
- Locations (2)
University Hospital Ghent
🇧🇪Ghent, Belgium
University Hospital Antwerp
🇧🇪Antwerp, Belgium